DK3094731T3 - Saccharidmodificerede nukleinsyremolekyler - Google Patents
Saccharidmodificerede nukleinsyremolekyler Download PDFInfo
- Publication number
- DK3094731T3 DK3094731T3 DK15700464.9T DK15700464T DK3094731T3 DK 3094731 T3 DK3094731 T3 DK 3094731T3 DK 15700464 T DK15700464 T DK 15700464T DK 3094731 T3 DK3094731 T3 DK 3094731T3
- Authority
- DK
- Denmark
- Prior art keywords
- saccharide
- nucleic acid
- acid molecules
- modified nucleic
- modified
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8216—Methods for controlling, regulating or enhancing expression of transgenes in plant cells
- C12N15/8218—Antisense, co-suppression, viral induced gene silencing [VIGS], post-transcriptional induced gene silencing [PTGS]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
- C12N15/8201—Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation
- C12N15/8206—Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation by physical or chemical, i.e. non-biological, means, e.g. electroporation, PEG mediated
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14151255 | 2014-01-15 | ||
PCT/EP2015/050685 WO2015107115A1 (en) | 2014-01-15 | 2015-01-15 | Saccharide-modified nucleic acid molecules |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3094731T3 true DK3094731T3 (da) | 2019-08-05 |
Family
ID=49989536
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK15700464.9T DK3094731T3 (da) | 2014-01-15 | 2015-01-15 | Saccharidmodificerede nukleinsyremolekyler |
Country Status (14)
Country | Link |
---|---|
US (1) | US10751425B2 (da) |
EP (1) | EP3094731B1 (da) |
JP (1) | JP6584412B2 (da) |
CN (1) | CN105899666B (da) |
BR (1) | BR112016014162A2 (da) |
DK (1) | DK3094731T3 (da) |
ES (1) | ES2742102T3 (da) |
HR (1) | HRP20191471T1 (da) |
HU (1) | HUE045086T2 (da) |
LT (1) | LT3094731T (da) |
PL (1) | PL3094731T3 (da) |
PT (1) | PT3094731T (da) |
SI (1) | SI3094731T1 (da) |
WO (1) | WO2015107115A1 (da) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015088990A1 (en) | 2013-12-09 | 2015-06-18 | Durect Corporation | Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same |
JP2019520342A (ja) | 2016-06-02 | 2019-07-18 | サノフイSanofi | グルコース感知タンパク質に結合することができる薬剤および部分のコンジュゲート |
EP3554551A1 (en) * | 2016-12-14 | 2019-10-23 | University College Cork-National University of Ireland, Cork | Cyclodextrin conjugates |
EP3728602A1 (en) * | 2017-12-21 | 2020-10-28 | baseclick GmbH | Click-modified mrna |
CA3089276A1 (en) * | 2018-02-17 | 2019-08-22 | Arrowhead Pharmaceuticals, Inc. | Trialkyne linking agents and methods of use |
US12065458B2 (en) | 2018-02-17 | 2024-08-20 | Arrowhead Pharmaceuticals, Inc. | Trialkyne linking agents and methods of use |
CN114901316B (zh) * | 2019-08-05 | 2024-02-13 | 宝利普拉斯生物转染公司 | 包含接枝到阳离子聚合物上的三唑化合物的用于将核酸分子转染到细胞中的组合物及其应用 |
CN111041025B (zh) | 2019-12-17 | 2021-06-18 | 深圳市瑞吉生物科技有限公司 | 基于结合N-乙酰半乳糖胺多肽的mRNA靶向分子及其制备方法 |
CN112111524B (zh) * | 2020-01-10 | 2024-02-27 | 深圳瑞吉生物科技有限公司 | mRNA-GalNAc靶向分子的制备方法及其体内递送系统和应用 |
CN111744019B (zh) * | 2020-07-01 | 2023-08-04 | 深圳瑞吉生物科技有限公司 | 基于甘露糖的mRNA靶向递送系统及其应用 |
WO2022094609A1 (en) * | 2020-10-30 | 2022-05-05 | Speer Tod | Oligonucleotide-based therapeutics and uses thereof |
WO2022226396A1 (en) * | 2021-04-23 | 2022-10-27 | Ganna Bio, Inc. | Glycan modified nucleic acids, methods of preparation, and therapeutic uses |
CA3232387A1 (en) * | 2021-09-13 | 2023-03-16 | Ganna Bio, Inc. | Glycan conjugate compositions and methods |
WO2023233395A1 (en) * | 2022-05-30 | 2023-12-07 | Nurexone Biologic Ltd. | Compositions and methods for loading extracellular vesicles |
CN115487308B (zh) * | 2022-09-29 | 2024-09-27 | 北京大学 | 反义核酸糖基缀合物及其制备方法和在肝癌治疗中的应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2352509T3 (es) | 2005-05-02 | 2011-02-21 | Baseclick Gmbh | Nuevas estrategias de marcaje para la detección sensible de analitos. |
JP2007044012A (ja) | 2005-08-12 | 2007-02-22 | Konan Gakuen | 葉の水分蒸散を調節する方法、及び植物の耐乾燥性を向上させる方法 |
AU2008290217B2 (en) * | 2007-08-20 | 2013-09-05 | Protalix Ltd. | Saccharide-containing protein conjugates and uses thereof |
EP4074344A1 (en) * | 2007-12-04 | 2022-10-19 | Arbutus Biopharma Corporation | Targeting lipids |
-
2015
- 2015-01-15 SI SI201530843T patent/SI3094731T1/sl unknown
- 2015-01-15 PT PT15700464T patent/PT3094731T/pt unknown
- 2015-01-15 PL PL15700464T patent/PL3094731T3/pl unknown
- 2015-01-15 WO PCT/EP2015/050685 patent/WO2015107115A1/en active Application Filing
- 2015-01-15 HU HUE15700464A patent/HUE045086T2/hu unknown
- 2015-01-15 BR BR112016014162-8A patent/BR112016014162A2/pt not_active Application Discontinuation
- 2015-01-15 JP JP2016543113A patent/JP6584412B2/ja active Active
- 2015-01-15 ES ES15700464T patent/ES2742102T3/es active Active
- 2015-01-15 DK DK15700464.9T patent/DK3094731T3/da active
- 2015-01-15 EP EP15700464.9A patent/EP3094731B1/en active Active
- 2015-01-15 LT LT15700464T patent/LT3094731T/lt unknown
- 2015-01-15 CN CN201580003755.XA patent/CN105899666B/zh active Active
- 2015-01-15 US US15/111,071 patent/US10751425B2/en active Active
-
2019
- 2019-08-14 HR HRP20191471 patent/HRP20191471T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
SI3094731T1 (sl) | 2019-10-30 |
HRP20191471T1 (hr) | 2019-11-15 |
BR112016014162A2 (pt) | 2018-01-09 |
WO2015107115A1 (en) | 2015-07-23 |
US10751425B2 (en) | 2020-08-25 |
HUE045086T2 (hu) | 2019-12-30 |
PT3094731T (pt) | 2019-09-04 |
PL3094731T3 (pl) | 2019-10-31 |
US20160333364A1 (en) | 2016-11-17 |
EP3094731A1 (en) | 2016-11-23 |
JP6584412B2 (ja) | 2019-10-02 |
CN105899666A (zh) | 2016-08-24 |
JP2017504322A (ja) | 2017-02-09 |
EP3094731B1 (en) | 2019-07-17 |
LT3094731T (lt) | 2019-10-25 |
CN105899666B (zh) | 2020-10-09 |
ES2742102T3 (es) | 2020-02-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3341482T3 (da) | Kunstige nukleinsyremolekyler | |
DK3433368T3 (da) | Transreplikerende rna | |
DK4023249T3 (da) | Nukleinsyrevacciner | |
SG11201704681QA (en) | Artificial nucleic acid molecules | |
HUE042283T2 (hu) | Antiszensz nukleinsav | |
HUE049405T2 (hu) | Nukleáz-közvetített DNS-összeállítás | |
DK3234132T3 (da) | Ligand-modificerede dobbeltstrengede nukleinsyrer | |
HUE047175T2 (hu) | Eljárások nukleinsavak tanulmányozására | |
DK4023755T5 (da) | Kunstige nukleinsyremolekyler til forbedret proteinudtrykkelse | |
DK3094731T3 (da) | Saccharidmodificerede nukleinsyremolekyler | |
DK3129487T3 (da) | Forbedrede nukleinsyrekonstruktioner til eukaryot genekspression | |
HK1244021A1 (zh) | 核酸構建體 | |
HK1243958A1 (zh) | 核酸構建體 | |
DK3188836T3 (da) | Dna-syntese | |
DK3167044T3 (da) | Mikrofluidindretning | |
DK3105250T3 (da) | Multispecifikke iga-bindingsmolekyler | |
DK3351633T3 (da) | Antisense-nukleinsyre | |
EP3156789C0 (en) | BIOSENSOR | |
DK3341479T3 (da) | LNA-G-Proces | |
DK3242685T3 (da) | Cxcr4-bindende molekyler | |
DK3110442T3 (da) | Modificerede meningokok-fhbp-polypeptider | |
EP3498724A4 (en) | NUCLEIC ACID COMPLEX | |
DK2952752T3 (da) | Afbøjnings-rørbøjning | |
EP3387414A4 (en) | BIOSENSOR | |
IL249254A0 (en) | Gene expression system |